%0 journal article
%@ 1582-1838
%A Wang, W.,Li, W.,Ou, L.,Flick, E.,Mark, P.,Nesselmann, C.,Lux, C.A.,Gatzen, H.H.,Kaminski, A.,Liebold, A.,Luetzow, K.,Lendlein, A.,Li, R.-K.,Steinhoff, G.,Ma, N.

%D 2011
%J Journal of Cellular and Molecular Medicine
%N 9
%P 1989-1998 
%R doi:10.1111/j.1582-4934.2010.01130.x
%T Polyethylenimine-mediated gene delivery into human bone marrow mesenchymal stem cells from patients
%U https://doi.org/10.1111/j.1582-4934.2010.01130.x
9 
%X Transplantation of mesenchymal stem cells (MSCs) derived from adult bone marrow has been proposed as a potential therapeutic approach for postinfarction left ventricular (LV) dysfunction. However, age-related functional decline of stem cells has restricted their clinical benefits after transplantation into the infarcted myocardium. The limitations imposed on patient cells could be addressed by genetic modification of stem cells. This study was designed to improve our understanding of genetic modification of human bone marrow derived mesenchymal stem cells (hMSCs) by polyethylenimine (PEI, branched with Mw 25 kDa), one of non-viral vectors that show promise in stem cell genetic modification, in the context of cardiac regeneration for patients. We optimized the PEI-mediated reporter gene transfection into hMSCs, evaluated whether transfection efficiency is associated with gender or age of the cell donors, analyzed the influence of cell cycle on transfection, and investigated the transfer of therapeutic vascular endothelial growth factor gene (VEGF).